Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill

Executive Summary

Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)
Advertisement

Related Content

BioShield House Compromise Could Serve As Template For Senate
BioShield House Compromise Could Serve As Template For Senate
PhRMA Urges Antitrust Exemption For Bioterrorism Research
“Project BioShield”: Industry Has Concerns, FDA Offers Support
Drug R&D For Global Diseases Needs Revenue Incentives – BIO Meeting
Vaccine Definition Refined In Homeland Security Bill To Include Thimerosal
Patent Incentive For Bioterrorism Research Offered In Lieberman Bill
Patent Incentive For Bioterrorism Research Offered In Lieberman Bill
BIO Vaccine Indemnification Proposal Would Require Govt. To Defend Suits
Indemnification Discussed For HHS-Contracted Smallpox Vaccine Producers
Advertisement
UsernamePublicRestriction

Register

PS040715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel